Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Isambert

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2007
Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analoguesP Fumoleau, B Coudert, N Isambert, et al.
International Journal of Oncology|June 28, 2014
Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review)L Magadoux, N Isambert, S Plenchette, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2009
Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapyN Penel, A Italiano, N Isambert, et al.
Cancer|August 22, 2000
Trends in incidence and management of gallbladder carcinoma: a population-based study in FranceS Manfredi, A M Benhamiche, N Isambert, et al.
European Journal of Gastroenterology & Hepatology|February 3, 2000
Cancer of the ampulla of Vater: results of a 20-year population-based studyA M Benhamiche, J L Jouve, S Manfredi, et al.
Cancer Chemotherapy and Pharmacology|November 3, 2011
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanesM Campone, N Isambert, E Bourbouloux, et al.
Investigational New Drugs|September 6, 2013
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)T Valentin, C Fournier, N Penel, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2006
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumorsM Campone, N Isambert, E Bourbouloux, et al.
Leukemia|June 24, 2000
Increase therapy-related leukemia secondary to breast cancerP M Carli, C Sgro, N Parchin-Geneste, et al.
Annales De Medecine Interne|August 3, 2000
[Malignant paraganglioma of the uterus]N Isambert, P Gros, P Commegeille, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2007
Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analoguesP Fumoleau, B Coudert, N Isambert, et al.
International Journal of Oncology|June 28, 2014
Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review)L Magadoux, N Isambert, S Plenchette, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2009
Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapyN Penel, A Italiano, N Isambert, et al.
Cancer|August 22, 2000
Trends in incidence and management of gallbladder carcinoma: a population-based study in FranceS Manfredi, A M Benhamiche, N Isambert, et al.
European Journal of Gastroenterology & Hepatology|February 3, 2000
Cancer of the ampulla of Vater: results of a 20-year population-based studyA M Benhamiche, J L Jouve, S Manfredi, et al.
Cancer Chemotherapy and Pharmacology|November 3, 2011
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanesM Campone, N Isambert, E Bourbouloux, et al.
Investigational New Drugs|September 6, 2013
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)T Valentin, C Fournier, N Penel, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2006
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumorsM Campone, N Isambert, E Bourbouloux, et al.
Leukemia|June 24, 2000
Increase therapy-related leukemia secondary to breast cancerP M Carli, C Sgro, N Parchin-Geneste, et al.
Annales De Medecine Interne|August 3, 2000
[Malignant paraganglioma of the uterus]N Isambert, P Gros, P Commegeille, et al.
Pageof 6